ليتوانيا - اللتوانية - SMCA (Valstybinė vaistų kontrolės tarnyba)

valentis, uab - skruzdžių rūgštis - odos tirpalas - 12 mg/ml - other topical products for joint and muscular pain

ليتوانيا - اللتوانية - SMCA (Valstybinė vaistų kontrolės tarnyba)

leo pharma a/s - metilprednizolono aceponatas - tepalas - 1 mg/g - methylprednisolone aceponate

ليتوانيا - اللتوانية - SMCA (Valstybinė vaistų kontrolės tarnyba)

dr. august wolff gmbh & co. kg arzneimittel - benzoilo peroksidas - gelis - 50 mg/g - benzoyl peroxide

ليتوانيا - اللتوانية - SMCA (Valstybinė vaistų kontrolės tarnyba)

bausch + lomb ireland limited - sulfatiazolo sidabro druska - kremas - 20 mg/g - sulfathiazole

ليتوانيا - اللتوانية - SMCA (Valstybinė vaistų kontrolės tarnyba)

gedeon richter plc - triamcinolono acetonidas - tepalas - 1 mg/g - triamcinolone

ليتوانيا - اللتوانية - SMCA (Valstybinė vaistų kontrolės tarnyba)

dr. kade pharmazeutische fabrik gmbh - lidokainas - tepalas - 50 mg/g - lidocaine

ليتوانيا - اللتوانية - SMCA (Valstybinė vaistų kontrolės tarnyba)

sia ingen pharma - klotrimazolas - kremas - 10 mg/g - clotrimazole

الاتحاد الأوروبي - اللتوانية - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritas, reumatas - imunosupresantai - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

الاتحاد الأوروبي - اللتوانية - EMA (European Medicines Agency)

leo pharma a/s - tralokinumab - dermatitas, atopinis - kiti dermatologiniai preparatai - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

الاتحاد الأوروبي - اللتوانية - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatitas, atopinis - kiti dermatologiniai preparatai - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.